Response Genetics Inc. to Offer FDA-Approved ALK Test for metastatic NSCLC.

RESPONSE Genetics Inc.; ANAPLASTIC lymphoma kinase; LUNG cancer treatment; FLUORESCENCE; GENE rearrangement; APOPTOSIS

The article informs that Response Genetics Inc. has announced the addition of new anaplastic lymphoma kinase (ALK) testing capabilities. The addition will help the company to better detect gene variants in patients with non-small cell lung cancer (NSCLC) by using fluorescence in situ hybridization (FISH). It is estimated that about 3-5 percent of NSCLC tumors have a rearrangement of the ALK gene, which can lead to impaired programmed cell death and abnormal cell growth.